Combination therapy with trimethoprim-sulfamethoxazole and caspofungin in a case of severe pneumocystis pneumonia

Trimethoprim-sulfamethoxazole (TMP-SMX, co-trimoxazole, or bactrim) has been the standard first-line treatment against Pneumocystis jirovecii pneumonia (PCP) for decades. However, adverse effects and cases of treatment failure have led to a search for alternative agents. We present a case of a 50 ye...

Descripción completa

Detalles Bibliográficos
Autores principales: Koshy, Robin, Chen, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6384316/
https://www.ncbi.nlm.nih.gov/pubmed/30828545
http://dx.doi.org/10.1016/j.idcr.2019.e00496
_version_ 1783396974320418816
author Koshy, Robin
Chen, Thomas
author_facet Koshy, Robin
Chen, Thomas
author_sort Koshy, Robin
collection PubMed
description Trimethoprim-sulfamethoxazole (TMP-SMX, co-trimoxazole, or bactrim) has been the standard first-line treatment against Pneumocystis jirovecii pneumonia (PCP) for decades. However, adverse effects and cases of treatment failure have led to a search for alternative agents. We present a case of a 50 year old immune compromised female whose course of PCP did not improve until Caspofungin was added to TMP-SMX.
format Online
Article
Text
id pubmed-6384316
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-63843162019-03-01 Combination therapy with trimethoprim-sulfamethoxazole and caspofungin in a case of severe pneumocystis pneumonia Koshy, Robin Chen, Thomas IDCases Article Trimethoprim-sulfamethoxazole (TMP-SMX, co-trimoxazole, or bactrim) has been the standard first-line treatment against Pneumocystis jirovecii pneumonia (PCP) for decades. However, adverse effects and cases of treatment failure have led to a search for alternative agents. We present a case of a 50 year old immune compromised female whose course of PCP did not improve until Caspofungin was added to TMP-SMX. Elsevier 2019-01-26 /pmc/articles/PMC6384316/ /pubmed/30828545 http://dx.doi.org/10.1016/j.idcr.2019.e00496 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Koshy, Robin
Chen, Thomas
Combination therapy with trimethoprim-sulfamethoxazole and caspofungin in a case of severe pneumocystis pneumonia
title Combination therapy with trimethoprim-sulfamethoxazole and caspofungin in a case of severe pneumocystis pneumonia
title_full Combination therapy with trimethoprim-sulfamethoxazole and caspofungin in a case of severe pneumocystis pneumonia
title_fullStr Combination therapy with trimethoprim-sulfamethoxazole and caspofungin in a case of severe pneumocystis pneumonia
title_full_unstemmed Combination therapy with trimethoprim-sulfamethoxazole and caspofungin in a case of severe pneumocystis pneumonia
title_short Combination therapy with trimethoprim-sulfamethoxazole and caspofungin in a case of severe pneumocystis pneumonia
title_sort combination therapy with trimethoprim-sulfamethoxazole and caspofungin in a case of severe pneumocystis pneumonia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6384316/
https://www.ncbi.nlm.nih.gov/pubmed/30828545
http://dx.doi.org/10.1016/j.idcr.2019.e00496
work_keys_str_mv AT koshyrobin combinationtherapywithtrimethoprimsulfamethoxazoleandcaspofungininacaseofseverepneumocystispneumonia
AT chenthomas combinationtherapywithtrimethoprimsulfamethoxazoleandcaspofungininacaseofseverepneumocystispneumonia

Ejemplares similares